Bryn T Haws1, Wei Cui1, Diane L Persons1, Da Zhang2. 1. Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS. 2. Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS. Electronic address: dzhang@kumc.edu.
Abstract
BACKGROUND: Only a few studies have investigated the presence of increased MYC gene copy number (ICN) as a prognostic indicator in patients with diffuse large B-cell lymphoma (DLBCL), and the results have been variable. We compared overall survival in patients with ICN to MYC-negative patients and investigated the prognostic significance of increased MYC gene copy number. PATIENTS AND METHODS: Two groups, those with MYC ICN (n = 33) and those with no MYC aberrations (n = 43), identified by fluorescence in-situ hybridization DNA probes for the MYC region at 8q24, were compared for survival (1-9 years), MYC immunohistochemical (IHC) protein expression, and treatment protocol. Comparison of cases of DLBCL with MYC ICN to those with no MYC aberration demonstrated no significant difference in survival (P = .58). Additionally, no difference in survival was found between patients with increased MYC protein expression (IHC MYC ≥ 40%) compared to those with IHC MYC < 40% (P = .5). RESULTS: Comparison of Ki-67 proliferation rates, stratified into low and high groups, did not achieve statistical significance (P = .67). Patients with MYC ICN showed a slightly increased MYC protein expression (P > .05). Importantly, the majority of patients in both groups (79% of patients with ICN and 81% of patients with no MYC aberrations) were treated with rituximab-based therapies. CONCLUSION: No significant difference in survival was found between patients with DLBCL with MYC ICN and patients with no MYC aberrations (P = .58). Copyright Â
BACKGROUND: Only a few studies have investigated the presence of increased MYC gene copy number (ICN) as a prognostic indicator in patients with diffuse large B-cell lymphoma (DLBCL), and the results have been variable. We compared overall survival in patients with ICN to MYC-negative patients and investigated the prognostic significance of increased MYC gene copy number. PATIENTS AND METHODS: Two groups, those with MYC ICN (n = 33) and those with no MYC aberrations (n = 43), identified by fluorescence in-situ hybridization DNA probes for the MYC region at 8q24, were compared for survival (1-9 years), MYC immunohistochemical (IHC) protein expression, and treatment protocol. Comparison of cases of DLBCL with MYC ICN to those with no MYC aberration demonstrated no significant difference in survival (P = .58). Additionally, no difference in survival was found between patients with increased MYC protein expression (IHC MYC ≥ 40%) compared to those with IHC MYC < 40% (P = .5). RESULTS: Comparison of Ki-67 proliferation rates, stratified into low and high groups, did not achieve statistical significance (P = .67). Patients with MYC ICN showed a slightly increased MYC protein expression (P > .05). Importantly, the majority of patients in both groups (79% of patients with ICN and 81% of patients with no MYC aberrations) were treated with rituximab-based therapies. CONCLUSION: No significant difference in survival was found between patients with DLBCL with MYC ICN and patients with no MYC aberrations (P = .58). Copyright Â
Authors: David Sermer; Sabela Bobillo; Ahmet Dogan; Yanming Zhang; Venkatraman Seshan; Jessica A Lavery; Connie Batlevi; Philip Caron; Audrey Hamilton; Paul Hamlin; Steven Horwitz; Erel Joffe; Anita Kumar; Matthew Matasar; Ariela Noy; Colette Owens; Alison Moskowitz; M Lia Palomba; David Straus; Gottfried von Keudell; Ildefonso Rodriguez-Rivera; Lorenzo Falchi; Andrew Zelenetz; Joachim Yahalom; Anas Younes Journal: Blood Adv Date: 2020-07-28